Tachykinin receptor antagonists in clinical trials

Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)

(2017) J. Herrstedt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)

(2017) J. Strausz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant

(2016) Ian Olver   Therapeutics and Clinical Risk Management

Ibodutant

(2009) S. Giuliani et al.   DRUGS OF THE FUTURE

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy

(2009) Karin Jordan et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

(2009) Steven M Grunberg et al.   LANCET ONCOLOGY

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

(2009) Brendan Johnson et al.   SUPPORTIVE CARE IN CANCER

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron

(2009) Laurel M. Adams et al.   SUPPORTIVE CARE IN CANCER

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting

(2008) Jon D. Herrington et al.   CANCER

Giving Permission

(2008) Steven M. Grunberg   JOURNAL OF CLINICAL ONCOLOGY

Across Generations: Cancer Treatment in Developing Countries

(2008) Zeba Aziz   JOURNAL OF CLINICAL ONCOLOGY

Neurokinin-1 Receptor Antagonist (Aprepitant) Suppresses HIV-1 Infection of Microglia/Macrophages

(2008) Xu Wang et al.   Journal of Neuroimmune Pharmacology

Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability

(2008) Lia Gore et al.   PEDIATRIC BLOOD & CANCER

Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism

(2008) D. T. George et al.   SCIENCE

Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

(2008) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

(2007) Caroline Louis et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR